Accelerating Cancer Research - Agilent’s Bravo Platform Helps Biotech Company Change The Game
Accelerating Cancer Research - Agilent’s Bravo Platform Helps Biotech Company Change The Game
2 PagesColin Sanctuary Founder and CEO QGel Lausanne, Switzerland ACCELERATING CANCER RESEARCH AGILENT’S BRAVO PLATFORM HELPS BIOTECH COMPANY CHANGE THE GAME AGILENT BRAVO SUCCESS STORY “To control how cancer grows” says Colin Sanctuary, “you must be able to control the microenvironment of the cancer.” Sanctuary is the founder and chief executive of QGel, a Swiss biotech company that uses Agilent technology to create microenvironments tailored to
